Haemonetics (NYSE:HAE) Updates FY25 Earnings Guidance

Haemonetics (NYSE:HAE) updated its FY25 earnings guidance on Thursday. The company provided EPS guidance of $4.45-4.75 for the period, compared to the consensus EPS estimate of $4.59. The company issued revenue guidance of ~$1.37-1.41 billion, compared to the consensus revenue estimate of $1.40 billion. Haemonetics also updated its FY 2025 guidance to 4.450-4.750 EPS.

Analysts Set New Price Targets

Several brokerages have recently weighed in on HAE. Citigroup decreased their price target on shares of Haemonetics from $94.00 to $85.00 and set a “neutral” rating for the company in a research note on Thursday, August 22nd. Barrington Research reissued an “outperform” rating and issued a $108.00 price objective on shares of Haemonetics in a report on Monday, September 23rd. JMP Securities reaffirmed a “market outperform” rating and set a $125.00 price target on shares of Haemonetics in a report on Tuesday, August 13th. CL King began coverage on Haemonetics in a report on Friday, September 13th. They set a “buy” rating and a $116.00 price target for the company. Finally, Bank of America assumed coverage on Haemonetics in a report on Wednesday, September 11th. They set a “neutral” rating and a $85.00 target price for the company. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $106.14.

Haemonetics Price Performance

Haemonetics stock traded up $6.15 during midday trading on Thursday, reaching $84.31. The company’s stock had a trading volume of 230,928 shares, compared to its average volume of 539,984. Haemonetics has a 52 week low of $70.25 and a 52 week high of $97.97. The company has a current ratio of 3.76, a quick ratio of 2.33 and a debt-to-equity ratio of 1.35. The business has a 50-day moving average price of $75.42 and a 200-day moving average price of $82.60. The stock has a market cap of $4.31 billion, a PE ratio of 35.05, a price-to-earnings-growth ratio of 1.15 and a beta of 0.32.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, August 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.03 by ($0.01). The business had revenue of $336.17 million during the quarter, compared to the consensus estimate of $335.08 million. Haemonetics had a net margin of 8.61% and a return on equity of 21.86%. The business’s revenue was up 8.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.05 EPS. On average, sell-side analysts predict that Haemonetics will post 4.57 EPS for the current year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.